PCOS Healthcare Trends · Evergreen explainer
Hair thinning and hormonal acne: the androgen connection, explained
Two of the most searched questions in this condition sound like opposites: why is hair growing where it is not wanted, and why is it thinning where it is? Add persistent acne that did not end with the teenage years, and many people assume three separate problems. In PCOS, now also called PMOS for polyendocrine metabolic ovarian syndrome, clinicians group all three under one heading, clinical hyperandrogenism, meaning visible signs of androgen effect on skin and hair. This piece explains how one hormone signal can produce opposite results in different follicles, what the largest evidence reviews actually found about acne and hair thinning in this condition, why the 2023 International Evidence-based Guideline treats each of these two signs more cautiously than excess hair growth, and which clinician handles which part of the conversation.
One signal, three different answers
Androgens are a group of hormones present in all sexes. Skin and hair follicles do not all answer them the same way, and that single fact explains most of the confusion around this topic:
- Oil glands. Androgens can increase sebum, the oil the skin makes. More sebum, together with clogged pores and the normal bacteria of the skin, is part of how acne forms. Our glossary defines androgens, sebum and related terms in plain language.
- Face and body follicles. In androgen-sensitive areas such as the chin and upper lip, androgens can shift fine, light hair toward coarse terminal hair. That sign has its own name, hirsutism, and its own explainer on this site: hirsutism, explained without embarrassment.
- Scalp follicles. On the top of the scalp, in follicles that are genetically susceptible, the same signal can run the process in reverse: hairs grow back finer and shorter each cycle, a change clinicians call miniaturisation, until density visibly falls. That pattern is called female pattern hair loss, sometimes shortened to FPHL, and also called androgenetic alopecia.
The word susceptible is doing real work in that list. Follicle sensitivity varies from person to person and runs in families, which is why visible signs and blood results do not always move together. A person can have acne or thinning with androgen levels inside the laboratory reference range, and a person can have raised androgens with clear skin and full hair. Extra insulin can be part of the picture too, because it can raise androgen activity and lower SHBG, the protein that keeps some androgen inactive. Our explainer on insulin resistance in PCOS/PMOS walks through that link in plain steps, and a 2025 narrative review in Cureus on acne in this condition describes the same two drivers, androgen effect compounded by insulin resistance, as the mechanism its authors found across the literature.
Acne in this condition: what the big reviews found
Acne in PCOS/PMOS is usually described as adult acne that persists past the teenage years or returns after a clear stretch, often alongside other features of the condition. Descriptions in the literature often mention the lower face and jawline, but no distribution on its own confirms or rules out a hormone link, and the guideline notes there is no universally accepted instrument for grading acne in this assessment. Clinicians describe what they see, where it is, and how severe it appears, rather than reading a single standard score the way they can for excess hair growth.
Two large meta-analyses give the scale of it, and reading them side by side teaches something about evidence as well as about skin:
- A 2021 meta-analysis in Gynecological Endocrinology pooled 60 studies covering 240,213 women with PCOS and 1,902,022 women without it. The authors reported acne in 43 percent of women with PCOS compared with 21 percent of controls, with higher pooled figures in adolescents (59 percent) than in adults (42 percent), and wide variation by which diagnostic definition a study used.
- A 2025 meta-analysis in the Medical Journal of the Islamic Republic of Iran pooled 95 studies and reported 49 percent (95 percent confidence interval 47 to 52 percent) before adjustment, and 37 percent after a trim-and-fill adjustment for publication bias. The authors reported very high inconsistency between studies and wide regional variation, from 32 percent in Europe to 76 percent in Oceania, with adolescents under 18 at 66 percent in their subgroup analysis.
Those two headlines, 43 percent and 49 percent, are not in conflict once the methods are visible: different study sets, different regions and ages, different diagnostic definitions, and one analysis adjusting for the tendency of striking results to be published more often. The honest summary is that acne is common in this condition, roughly twice as common as in comparison groups in the largest pool, more common in adolescents than adults, and variable enough by setting that no single percentage describes any one clinic, let alone any one person.
Hair thinning: the pattern clinicians look for
Female pattern hair loss in this condition is usually a slow, diffuse thinning over the top and crown of the scalp. The earliest change people report is a widening centre part, then visible scalp under bright light, and a ponytail that feels smaller than it used to. The front hairline is usually preserved, which is one reason the change can be well advanced before it is named. It is a pattern of gradual miniaturisation, not a sudden shedding.
That pattern matters because other kinds of hair loss look different and point elsewhere, and a good workup separates them:
- Sudden shedding a few months after an illness, a major stress, childbirth, or a rapid weight change is a different pattern (clinicians call it telogen effluvium) and is usually about timing, not androgens.
- Round, smooth patches of complete loss suggest a different condition again (alopecia areata) and a dermatology-led workup.
- Loss with pain, scaling, or scarring, or loss at the front hairline with recession, needs prompt dermatology assessment, because some scarring hair conditions are time-sensitive in a way pattern thinning is not.
- Thyroid problems, low iron stores, and some medicines can also thin hair, which is why a scalp complaint usually earns a broader set of questions and, where a clinician judges it useful, blood work beyond androgens.
For grading, the 2023 guideline points clinicians to standardised visual scales: the Ludwig scale, which grades loss of density over the crown in three stages, and the Olsen scale, which describes a triangular widening of the part toward the front, sometimes called a Christmas tree pattern. A grade recorded the same way at each visit, or dated photographs taken in the same light and parting, tell a clinician more than comparing the shower drain from week to week, because normal daily shedding varies and is a poor measure of pattern change.
The guideline is careful with these two signs, and says why
The 2023 International Evidence-based Guideline lists acne, female pattern hair loss and hirsutism together as the signs a complete history and examination should cover in adults. It then ranks their diagnostic weight differently, in one of its most quoted recommendations: healthcare professionals could recognise that female pattern hair loss and acne in isolation, without hirsutism, are relatively weak predictors of biochemical hyperandrogenism. Hirsutism alone, by contrast, should be considered predictive of it. Our explainer on how PCOS/PMOS is diagnosed sets out where androgen excess sits in the 2-of-3 rule these signs feed into, and our piece on the four PCOS/PMOS phenotypes shows the combinations that rule produces.
Weak predictor needs translating, because it is often misread as does not matter. It means this: acne alone, or thinning alone, does a poor job of forecasting what an androgen blood test will show. Both are common, both have many causes, and both frequently occur with hormone levels in the reference range. So neither sign, on its own, settles a diagnosis, and neither should be waved away either. The guideline makes that second half explicit in a separate recommendation: clinicians should be aware of the potential negative psychosocial impact of clinical hyperandrogenism, and should consider a report of unwanted excess hair growth or female pattern hair loss as important regardless of apparent clinical severity. In plain terms, if thinning is distressing you, that distress and the pattern you describe belong in the record even when the loss looks early or mild in the room.
What a 2025 review of hair loss and PCOS found, in both directions
In 2025, researchers published a systematic review and meta-analysis in JAAD International that asked the association question both ways. Searching the literature to December 2024, they included 24 observational studies. In the 18 studies that assessed hair loss in patients with PCOS (3,464 patients), the pooled prevalence of female pattern hair loss was 22.7 percent, with a 95 percent confidence interval of 16.9 to 29.7 percent. In the 6 studies that assessed PCOS in patients with hair loss (1,583 patients), the pooled prevalence of PCOS was 32.3 percent, with a much wider interval of 13.6 to 59.1 percent.
The authors graded their own certainty, and an honest explainer keeps those grades attached: low certainty for the first figure, because the studies were very inconsistent with each other, and very low certainty for the second, with serious risk of bias added. They also noted that both conditions are probably underdiagnosed in the underlying studies, and that the designs were cross-sectional, a snapshot rather than a follow-up, so the review shows association, not cause, and cannot say whether having this condition makes hair loss faster or more severe for any individual. Read plainly, the review supports two modest conclusions: about one in five to one in four people with PCOS in these study groups had pattern hair loss, which also means most did not; and PCOS is common enough among people presenting with pattern hair loss that asking about cycles and other features is a reasonable part of that workup.
Why both signs are judged in months, not weeks
Patients often ask how soon a change should be visible, and the honest answer starts with biology rather than with any product. Scalp hair grows in long cycles, and a follicle that has miniaturised does not announce a change of direction quickly; clinicians grading pattern loss therefore talk in seasons, comparing the same scale grade or the same dated photograph months apart. Skin turns over faster than hair, but acne also fluctuates with cycles, stress, illness and products, so a single good or bad week is weak evidence about any direction. This page makes no claim about what any treatment, medicine or product does for either sign. What it can say is that the useful question at a follow-up visit is a measurement question: can we grade or photograph this the same way we did last time, and what change, over what period, would we count as real? Our guide to questions to bring to a first appointment shows how to set that record up from the first visit.
Which clinician handles which part
- A dermatologist usually leads on the skin and scalp themselves: confirming which kind of acne or hair loss is present, grading thinning with a Ludwig or Olsen scale, examining the scalp up close, and sorting look-alike causes such as shedding after illness or patchy loss. What options sit in that lane, and what any of them might mean for a given person, is a decision for that visit. This page ranks none of them.
- An endocrinologist leads when the hormone side needs deeper sorting: whether androgen levels are raised, whether another endocrine cause is in question, and how the metabolic screening that travels with this condition is coordinated.
- Primary care or an OB-GYN usually holds the whole picture: the cycle history, the first examination and blood work the guideline directs, and the referrals that connect dermatology and endocrine so the signs are not treated as three unrelated complaints.
- Mental health support belongs in the picture when the impact is heavy. The guideline treats psychological features as part of assessment in this condition, and visible skin and hair changes are one of the places that impact shows up most plainly.
Our piece on which clinician does what maps that team in full, including dietitians and reproductive endocrinologists.
What this does not mean
- Acne alone is not a PCOS diagnosis, and neither is hair thinning alone. The guideline calls each, in isolation, a relatively weak predictor of raised androgens. A diagnosis needs the full pattern, with other causes considered first.
- A PCOS diagnosis is not a prediction that you will lose scalp hair. In the largest pooled review, most people with the condition did not have pattern hair loss recorded.
- Normal androgen results do not erase a real pattern. Follicle and oil-gland sensitivity vary, so visible signs and blood results often disagree. That disagreement is a known feature of this condition, not proof that nothing is happening.
- More severe acne does not mean proportionally higher androgens. Severity, blood levels and follicle response are three related but separate things, which is why clinicians assess all three rather than inferring one from another.
- This page names no treatment as right for you. It gives no doses, ranks no product, procedure or programme, and describes no result you should expect. Those decisions depend on your full workup and your own priorities, made with your clinician.
Questions to bring to an appointment about acne or hair thinning
- Can we record what kind of acne or hair loss this is, in words, and grade the thinning with a Ludwig or Olsen scale so we can compare it at the next visit?
- Given that acne and thinning alone are weak predictors, do I need androgen blood work, and if so, which tests, and how does hormonal contraception affect how we read them?
- What other causes have we considered for this pattern, for example thyroid, iron stores, recent illness or shedding after a major change?
- How do these signs sit alongside my cycle pattern and the rest of my workup? Which of the three diagnostic features do I actually have?
- Should dermatology be part of my care, and who coordinates between dermatology, endocrine and my main clinician?
- How will we judge change over time: the same scale, dated photographs in the same light, and over what period?
- Can the impact this is having, time, cost and distress, be written into my record, not only the grade?
What this means when you are finding care
The clinician you want can name which kind of acne or hair loss you have, grade it with a standard scale where one exists, explain why blood work does or does not follow from it, and state plainly what would make them look for a different cause. You can search the directory for PCOS/PMOS-focused providers by state, provider type and telehealth, browse by state, for example the Florida listings page, and skim the plain-language glossary before a visit.
Sources
- Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, Journal of Clinical Endocrinology and Metabolism, 2023, including section 1.3 on clinical hyperandrogenism (acne and female pattern hair loss in isolation as relatively weak predictors, comprehensive history covering acne, hair loss and hirsutism, reports of hair loss as important regardless of apparent severity, and standardised visual scales including Ludwig and Olsen for hair loss) — read the guideline (PMC)
- Rayner DG, et al. Bi-directional association between female pattern hair loss and polycystic ovary syndrome: a systematic review and meta-analysis, JAAD International, 2025 (24 observational studies; pooled FPHL prevalence 22.7 percent in PCOS across 18 studies and 3,464 patients, low certainty; pooled PCOS prevalence 32.3 percent in FPHL across 6 studies and 1,583 patients, very low certainty) — read the review (PMC)
- Pourahmad B, et al. Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systematic review and meta-analysis, Medical Journal of the Islamic Republic of Iran, 2025 (95 studies; pooled 49 percent, trim-and-fill adjusted 37 percent, high inconsistency between studies) — read the review (PMC) · abstract (PubMed)
- Ramezani Tehrani F, et al. Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systematic review and meta-analysis, Gynecological Endocrinology, 2021 (60 studies; 240,213 women with PCOS and 1,902,022 controls; acne 43 percent compared with 21 percent) — read the abstract (PubMed)
- Damoulaki E, et al. Polycystic ovary syndrome-associated acne: the interplay of hyperandrogenism, insulin resistance, and therapeutic strategies, Cureus, 2025, narrative review of mechanism and evidence — read the abstract (PubMed)
- The guideline programme home at Monash University — Monash Centre for Health Research and Implementation, PCOS
- Federal overview of the condition — NICHD, PCOS topic page
- Top-ranking explainer used as the bar for this piece — Ginger Healthcare, PCOS specialty overview
Looking for care? Find a PCOS/PMOS-focused provider or browse by state.
This article is general information published by the PMOS Directory. It is not medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. It does not describe what any treatment does for any person, and it is not a recommendation for or against any treatment, product, or provider. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition. If this is an emergency, call 911.